Search results for "risk reduction"

showing 10 items of 156 documents

Changes in life expectancy for cancer patients over time since diagnosis

2019

Highlights • Research question: how cancer impacts on LE changes during patients’ entire life • LE increased in patients surviving the first years and decreasing thereafter. • Patients’ LE in the end approached but seldom reached the general population’s LE. • This method describes when cancer survivors’ excess risk of death became negligible. • Life expectancy indicator is easy to be understood and interpreted by patients.

0301 basic medicinePediatricsmedicine.medical_specialtycancer survivorLife expectancyCancer survivorsPopulationYLL years of life lost(ICD-O-3) international classification of diseases for oncology third revisionSocio-culturaleLife expectancy Population-based cancer registry Relative survival Cancer Cancer survivors ItalySettore MED/42 - Igiene Generale E ApplicataRelative survival03 medical and health sciences0302 clinical medicineHealth careMedicineeducationlcsh:Science (General)Population-based cancer registryThyroid cancerCancerRS relative survivaleducation.field_of_studylcsh:R5-920MultidisciplinaryRelative survivalbusiness.industryAbsolute risk reductionCancermedicine.diseaseLE life expectancyNHL non-Hodgkin lymphoma030104 developmental biologyYears of potential life lostItalyISTAT national institute of statistics030220 oncology & carcinogenesisLife expectancy(ICD-10) international classification of diseases tenth revisionOriginal Articlebusinesslcsh:Medicine (General)lcsh:Q1-390Journal of Advanced Research
researchProduct

Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.

2020

Abstract Background and aims Polyvascular disease (PVD) affects approximately 20% of patients with atherosclerosis and is a strong independent risk factor for ischemic outcomes. However, guidelines do not address screening or treatment for PVD, and there have been no PVD-specific trials. We reviewed subgroup analyses of large randomized controlled trials of more intense antithrombotic therapy to determine whether increased intensity of therapy improved ischemic outcomes in patients with PVD. Methods MEDLINE, MEDLINE in-Process, EMBASE, and the Cochrane Library were queried for randomized controlled trials larger than 5000 patients evaluating secondary prevention therapies in patients with c…

0301 basic medicineRelative risk reductionmedicine.medical_specialtyPopulationCoronary Artery Disease030204 cardiovascular system & hematologyCochrane Librarylaw.invention03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawRisk FactorsInternal medicineAntithromboticmedicineHumansRisk factoreducationeducation.field_of_studybusiness.industryAbsolute risk reductionAtherosclerosis030104 developmental biologyRelative riskCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsAtherosclerosis
researchProduct

Stagewise pseudo-value regression for time-varying effects on the cumulative incidence

2015

In a competing risks setting, the cumulative incidence of an event of interest describes the absolute risk for this event as a function of time. For regression analysis, one can either choose to model all competing events by separate cause-specific hazard models or directly model the association between covariates and the cumulative incidence of one of the events. With a suitable link function, direct regression models allow for a straightforward interpretation of covariate effects on the cumulative incidence. In practice, where data can be right-censored, these regression models are implemented using a pseudo-value approach. For a grid of time points, the possibly unobserved binary event s…

0301 basic medicineStatistics and ProbabilityCarcinoma HepatocellularTime FactorsEpidemiologyComputer scienceFeature selectionBiostatistics01 natural sciences010104 statistics & probability03 medical and health sciencesRisk FactorsStatisticsCovariateEconometricsHumansComputer SimulationCumulative incidenceRegistries0101 mathematicsEvent (probability theory)Models StatisticalIncidenceLiver NeoplasmsAbsolute risk reductionRegression analysisRegression030104 developmental biologyRegression AnalysisJackknife resamplingAlgorithmsStatistics in Medicine
researchProduct

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)

2018

Abstract Background Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, results from mutations in SMPD1, the gene encoding acid sphingomyelinase (ASM). As a result, sphingomyelin accumulates in multiple organs including spleen, liver, lung, bone marrow, lymph nodes, and in the most severe form, in the CNS and peripheral nerves. Clinical manifestations range from rapidly progressive and fatal infantile neurovisceral disease, to less rapidly progressing chronic neurovisceral and visceral forms that are associated with significant morbidity and shorter life span due to respiratory or liver disease. Objectives To provide a contemporary guide of clinical assessments for di…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030105 genetics & heredityBiochemistryArticle03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyQuality of lifeInternal medicineGeneticsmedicineLysosomal storage diseaseHumansEnzyme Replacement TherapyMolecular BiologyMonitoring PhysiologicPatient monitoringClinical Trials as TopicAcid sphingomyelinase deficiencyASMDLungbusiness.industryDisease ManagementEnzyme replacement therapyNiemann-Pick Disease Type Amedicine.diseasePhenotypemedicine.anatomical_structureMutationPractice Guidelines as TopicQuality of LifeBone marrowAcid sphingomyelinasebusinessRisk Reduction Behavior030217 neurology & neurosurgerymedicine.drugMolecular Genetics and Metabolism
researchProduct

Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases. A Consensus Document by the Italian Society …

2021

Hypertension is a major contributor to fatal/nonfatal cardiovascular diseases, and timely identification and appropriate management of factors affecting hypertension and its control are mandatory public health issues. By inducing neurohormonal alterations and metabolic impairment, sleep disorders have an impact on a variety of cardiovascular risk factors, including hypertension, and ultimately increase the risk of cardiovascular events. There is evidence that qualitative and quantitative sleep disorders are associated with resistant hypertension and with impaired circadian blood pressure variations. However, sleep disturbances are often unrecognized, or heterogeneity exists in their managem…

0301 basic medicinemedicine.medical_treatmentSleep disorders.Comorbidity0302 clinical medicineCardiovascular DiseaseSleep Initiation and Maintenance DisordersInsomniaContinuous positive airway pressureSleep Apnea ObstructiveContinuous Positive Airway Pressureblood pressureHeart Disease Risk FactorPrognosisSleep in non-human animalsCircadian RhythmAntihypertensive AgentCardiovascular Diseasessleep disordersmedicine.symptomCardiology and Cardiovascular MedicineRisk assessmentHumancardiovascular riskmedicine.medical_specialtyConsensusSleep ApneahypertensionPrognosiConsensuRisk Assessment03 medical and health sciencesTherapeutic approachInternal MedicinemedicineHumansHealthy LifestyleIntensive care medicineConsensus DocumentAntihypertensive AgentsBlood pressure; Cardiovascular risk; Hypertension; Sleep disorders; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Comorbidity; Consensus; Healthy Lifestyle; Heart Disease Risk Factors; Humans; Hypertension; Prognosis; Risk Assessment; Risk Reduction Behavior; Sleep Apnea Obstructive; Sleep Initiation and Maintenance Disorders; Continuous Positive Airway Pressure; SleepSleep disorderbusiness.industryObstructivePublic healthmedicine.diseaseComorbidity030104 developmental biologyBlood pressureHeart Disease Risk Factorsblood pressure; cardiovascular risk; hypertension; sleep disordersbusinessSleepRisk Reduction Behavior030217 neurology & neurosurgery
researchProduct

People with Disabilities and Disasters

2017

Investigations have collectively established that disasters affect people with disabilities both disproportionately and negatively. In addition, perceived disability status is often associated with stigma, creating a separate and unique barrier across societies and cultures, which can augment vulnerability to disasters. Relevant research is reviewed by academic genesis areas in this chapter, namely; 1) disaster-focused research, 2) mental health, 3) epidemiology and public health, and 4) disability studies. Research emanating from these disciplines reflects different epistemological assumptions about disability as well as varying knowledge about disability as a social and cultural const…

030506 rehabilitation021110 strategic defence & security studiesmedicine.medical_specialtyInclusion (disability rights)Disaster risk reductionbusiness.industryPublic health0211 other engineering and technologiesVulnerabilityDisaster recovery02 engineering and technologyPublic relationsMental healthDisability studies03 medical and health sciencesPreparednessmedicine0305 other medical sciencebusinessPsychology
researchProduct

Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies

2016

Objective: To test previous signals of a risk of orofacial cleft (OC) and clubfoot with exposure to the antiepileptic lamotrigine, and to investigate risk of other congenital anomalies (CA).Methods: This was a population-based case–malformed control study based on 21 EUROCAT CA registries covering 10.1 million births (1995–2011), including births to 2005 in which the clubfoot signal was generated and a subsequent independent study population of 6.3 million births. A total of 226,806 babies with CA included livebirths, stillbirths, and terminations of pregnancy following prenatal diagnosis. First-trimester lamotrigine monotherapy exposure in OC cases and clubfoot cases was compared to other …

115congenital anomalies ; orofacial clefts ; lamotrigine ; pregnancy0302 clinical medicinePregnancyOdds RatioRegistries030212 general & internal medicineEPILEPSYeducation.field_of_studyTriazinesObstetricsAbsolute risk reductionANTIEPILEPTIC DRUGSAbnormalities Drug-InducedCleft PalateEuropeAnesthesiaINCREASED FREQUENCYAnticonvulsantsFemalemedicine.drugAdultRisk61medicine.medical_specialtyCleft LipPopulationPrenatal diagnosisLamotrigineLamotrigineSensitivity and SpecificityArticle03 medical and health sciencesJournal ArticlemedicineHumansAbnormalities Drug-Induced/epidemiology; Adult; Anticonvulsants/adverse effects; Anticonvulsants/therapeutic use; Case-Control Studies; Cleft Lip/chemically induced; Cleft Lip/epidemiology; Cleft Palate/chemically induced; Cleft Palate/epidemiology; Epilepsy/drug therapy; Epilepsy/epidemiology; Europe/epidemiology; Female; Humans; Odds Ratio; Pregnancy; Pregnancy Complications/drug therapy; Pregnancy Complications/epidemiology; Pregnancy Trimester First; Registries; Risk; Sensitivity and Specificity; Triazines/adverse effects; Triazines/therapeutic useMALFORMATIONSeducationPregnancy53business.industryCLUBFOOTCase-control studyOdds ratio228medicine.diseaseConfidence intervalPregnancy ComplicationsPregnancy Trimester FirstPALATECase-Control StudiesREGISTRYNeurology (clinical)business030217 neurology & neurosurgeryNeurology
researchProduct

Cuatro fórmulas de posicionamiento frente a las drogas

2010

Las políticas públicas en materia de drogas se encuentran actualmente en una encrucijada. A través de las siguientes páginas se ofrece una reflexión sobre cuatro tipos de posicionamiento teórico, cuatro formas diferentes de entender cuál es el papel que en este conflicto, deben adoptar los Estados. A modo de tipificación de esas perspectivas posibles, se ofrece una propuesta de clasificación distribuida en cuatro posiciones: - Prohibicionismo ideológico - Prohibicionismo político - Disminución del riesgo y reducción del daño - Negación de riesgos y daños Public policies on drugs are currently in a crossroad. Throughout the following pages four theoretical positions are examined, four differ…

:SOCIOLOGÍA::Cambio y desarrollo social [UNESCO]UNESCO::SOCIOLOGÍA::Cambio y desarrollo socialDrogas reducción de daños reducción de riesgos prohibicionismo políticas públicas. Drugs harm reduction risk reduction prohibition public policies Artículo
researchProduct

Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER…

2021

Abstract Aims In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice/day plus aspirin 100 mg/day was assessed in older adults. Advanced age is associated with elevated bleeding risk and unfavourable net benefit for dual antiplatelet therapy in chronic coronary artery disease. The risk–benefit of low-dose rivaroxaban in patients ≥75 years with peripheral artery disease (PAD) after lower extremity revascularization (LER) has not been described. Methods and results The primary endpoint was a composite of acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke, or cardiovascular death. The principal safety outcome was thrombolysis in myocardial infarct…

Acute limb ischaemiamedicine.medical_specialtyBrain IschemiaPeripheral Arterial DiseaseRivaroxabanInternal medicineClinical endpointHumansMedicineMyocardial infarctionAgedRivaroxabanAspirinbusiness.industryAbsolute risk reductionNumber needed to harmmedicine.diseaseStrokeCardiologyNumber needed to treatDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsTIMIFactor Xa Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct

A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in c…

1996

To estimate the risk of developing cervical intra-epithelial neoplasia (CIN) among women exposed to human papillomavirus (HPV) type 16, we performed a prospective study in a population-based cohort of more than 15,000 women followed for 34.9 months. Seventy-four women developed CIN during follow-up and were matched for age, time of sampling and area of residence with 148 women who remained CIN-free during follow-up. The blood samples taken at enrollment were tested for serum antibodies to HPV types 16, 18 and 33 capsids. Cervical smears or biopsies were analyzed for the presence of HPV DNA by nested PCR using HPV general primers and by HPV 16- and 18-type-specific PCR. HPV serology and HPV-…

AdultCancer Researchmedicine.medical_specialtyPopulationCervix UteriAntibodies ViralPolymerase Chain ReactionSerologyCohort StudiesRisk FactorsInternal medicineCarcinomamedicineHumansProspective StudiesRisk factorProspective cohort studyeducationPapillomaviridaeSwedenVaginal SmearsGynecologyeducation.field_of_studybusiness.industryPapillomavirus InfectionsAge FactorsAbsolute risk reductionvirus diseasesMiddle AgedUterine Cervical Dysplasiamedicine.diseasefemale genital diseases and pregnancy complicationsTumor Virus InfectionsOncologyDNA ViralCohortFemalebusinessPapanicolaou TestCohort studyInternational Journal of Cancer
researchProduct